Lixazinone hydrogensulfate
Lixazinone (RS-82856) hydrogensulfate is a selective inhibitor of cGMP-inhibited phosphodiesterase (PDE3) with an IC50 value of 22 nM. Lixazinone hydrogensulfate exhibits positive inotropic effects, afterload reduction and antithrombotic properties. Lixazinone hydrogensulfate increases cyclic adenosine monophosphate (cAMP) levels in human platelets, inhibits thrombin-induced aggregation of human platelets, and blocks the photolabeling of PDE3 active sites by [32P]cGMP. Lixazinone hydrogensulfate can be used in the research of polycystic kidney disease and congestive heart failure.
For research use only. We do not sell to patients.
- CAS No.: 101626-67-9
- Formula: C21H32N4O8S
- Molecular Weight:500.57
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
|
PDE3 22 μM (IC50) |
Lixazinone (0.5-1 μM; 5 min at 30 °C) hydrogensulfate potently and selectively inhibits human platelet PDE3, with 0.5 μM causing 97% inhibition of PDE3 activity and minimal effect on PDE2 activity at 1 μM[1].
Lixazinone (1 μM; 1 min at 37 °C) hydrogensulfate increases [3H]cAMP levels in human platelets by 177%[1].
Lixazinone (1 μM; 1 min at 37 °C pre-incubation) hydrogensulfate fully inhibits thrombin-induced aggregation in human platelets[1].
Lixazinone hydrogensulfate (1 μM; 1 min at 37 °C) moderately increases [3H]cAMP levels in human platelets treated with 20 nM PGI2[1].
Lixazinone (300 nM; 15 min dark at 0°C, 15 min UV irradiation) hydrogensulfate inhibits photolabelling of the 115 kDa PDE III subunit in rat platelet lysate and rat heart homogenate[2].
Lixazinone (10 μM; 60 min) hydrogensulfate increases intracellular cAMP levels by 22% in quiescent MDCK cells[3].
Lixazinone (10 μM) hydrogensulfate activates PKA by 27% in transfected quiescent MDCK cells[3].
Lixazinone (10 μM; 72 hrs) hydrogensulfate significantly stimulates mitogenesis in quiescent MDCK cells, as measured by [3H]-thymidine incorporation[3].
Lixazinone (10 μM; 5 mins) hydrogensulfate significantly activates B-Raf kinase activity, with no effect on Raf-1 kinase activity, in quiescent MDCK cells[3].
Lixazinone (10 μM; 1 hr) hydrogensulfate increases ERK kinase activity by 810% in quiescent MDCK cells[3].
Lixazinone (10 μM; 4 hrs) hydrogensulfate stimulates cyclin D kinase activity by 83% and cyclin E kinase activity by 58% in quiescent MDCK cells[3].
Lixazinone (10 μM; 8 hrs) hydrogensulfate does not significantly alter expression of p21 or p27 in quiescent MDCK cells[3].
Lixazinone (10 μM; 24 hrs) hydrogensulfate potently inhibits mitogenesis in rat glomerular mesangial cells, as measured by [3H]-thymidine incorporation[3].
Lixazinone (1 nM-10 μM) hydrogensulfate inhibits cAMP phosphodiesterase activity in total homogenates of cultured primary rat mesangial cells with an IC50 of 2.85 nM, a potency that correlates with its suppression of mitogenesis[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Primary rat mesangial cells
-
Concentration:1 μM
-
Incubation Time:16 h (overnight incubation; followed by 4 h [3H]thymidine pulse)
-
Result:Reduced [3H]thymidine incorporation by 46% relative to basal values, with a statistically significant effect.
Chemical Information
-
CAS No. 101626-67-9
-
Molecular Weight 500.57
-
Formula C21H32N4O8S
-
SMILES
O=C1N=C2NC3=CC=C(C=C3CN2C1)OCCCC(N(C4CCCCC4)C)=O.O=S(O)(O)=O.O
-
Synonyms
RS-82856 hydrogensulfate
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Dickinson NT, et al. Activation of cGMP-stimulated phosphodiesterase by nitroprusside limits cAMP accumulation in human platelets: effects on platelet aggregation. Biochem J. 1997;323 ( Pt 2)(Pt 2):371-377. [Content Brief]
[2]. Tang KM, et al. Photoaffinity labelling of cyclic GMP-inhibited phosphodiesterase (PDE III) in human and rat platelets and rat tissues: effects of phosphodiesterase inhibitors. Eur J Pharmacol. 1994;268(1):105-114. [Content Brief]
[3]. Cheng J, et al. Lixazinone stimulates mitogenesis of Madin-Darby canine kidney cells. Exp Biol Med (Maywood). 2006;231(3):288-295. [Content Brief]
[4]. Chini CC, et al. Compartmentalization of cAMP signaling in mesangial cells by phosphodiesterase isozymes PDE3 and PDE4. Regulation of superoxidation and mitogenesis. J Biol Chem. 1997 Apr 11;272(15):9854-9. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
- Lixazinone hydrogensulfate
- 101626-67-9
- RS-82856 hydrogensulfate
- Phosphodiesterase (PDE)
- human platelets
- cyclic adenosine monophosphate (cAMP)
- polycystic kidney diseases
- cGMP-inhibited phosphodiesterase (PDE3)
- renal cells
- thrombosis
- human PDE3
- protein kinase A (PKA)
- rat PDE3
- mesangial proliferative glomerulonephritis
- Inhibitor
- inhibitor
- inhibit